35 results about "Corneal disease" patented technology

Ophthalmically acceptable compositions used in arresting the development of macular degeneration, retinopathy, glaucoma, eyelid disorders, corneal disease, or uveitis are disclosed. The compositions comprise a pharmaceutically acceptable carrier or diluent and at least one compound having the formula:wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein.

A compound represented by formula (1) (wherein R1 represents a hydrogen atom or a carboxyl group, R2 represents a hydrogen atom or a hydroxy group, R3 represents a hydrogen atom or a carboxyl group, and R4 represents a hydrogen atom or a hydroxy group) or a pharmaceutically acceptable salt thereof is effective as a therapeutic agent or a prophylactic agent for a corneal disease or sensory nerve damage due to corneal surgery, and as a regeneration accelerator for corneal sensory nerves.

In the present invention an embryo or adult cornea epithelium is cut, digested with digesting liquid and centrifugated to prepare single cell suspension, and the cell suspension is cultured in culture dish or bottle with proper amount of culture medium and CO2 in 5% at 37 deg.c. The cultured cell is passed after cell converges to 80-90% and the second and sixth generation of cell is passed directly to amnion for culture for another 8-20 days to obtain the stem cell regenerating surface cornea of the present invention. The stem cell regenerating surface cornea may be used as material for treating corneal disease. The present invention provides a new material for treating corneal disease with rich material source, no danger of mouse-originated pollution, no or slight immunological rejection.

A medical cornea patch and its preparing method are disclosed, which implants autogenous mesenchyma stem cell to amnion for being carrier to treat cornea disease. The process includes: obtaining bone marrow 10ml from healthy person in clinical practice, diluting by PBS in ratio of 1:1, adding 5ml of Ficoll, centrifuging for 20 minutes, sucking out the nebulous single nuclei cell suspension, washing three times by PBS, implanting to 10% FBS containing culture medium of a-MEM, fetching 2X105 cell of the fourth generation to treated amnion with size of 1.5cmX1.5cm after 10 to 14 days, adding to culture medium to continue culturing, till the cell grow fully of the whole amnion.

A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating / ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient.

Subject: To provide a method for producing human corneal epithelial sheets for transplantation to patients with corneal diseases, and for culturing cells derived from human corneal epithelium obtained by culturing human corneal epithelial cells on stromal amniotic membrane. Solution: culture method of human corneal epithelial cells using human mesenchymal stem cells as supporting cells, and using various combinations of ROCK inhibitors, phosphodiesterase inhibitors, MAP kinase inhibitors, and TGF‑β receptor inhibitors culture medium of human corneal epithelial cells.

The present invention pertains to a novel means for treating corneal diseases. The present invention provides a therapeutic agent for corneal diseases, which contains a compound represented by formula (I) or a salt thereof (the definition of each symbol in the formula is as described in the description).

The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.

The invention discloses a method for screening the transparency of a film-shaped heterogeneous biological material, which comprises the steps of dehydration of the biological material sucrose, OCT embedding, layer-by-layer frozen sectioning, and light transmittance measurement with a spectrophotometer. Also provided is a highly transparent decellularized dermal matrix obtained by the above method. Through the present invention, the acellular dermal matrix with the best transparency can be effectively screened out, which can be used for lamellar keratoplasty, and the surgeon can use the above-mentioned matrix to replace the existing lamellar corneal stroma during the operation. At the same time, it can also effectively solve the contradiction of the current shortage of donor corneas.

The present invention relates to a novel means for treating corneal diseases. The present invention provides a therapeutic agent for corneal diseases, containing a compound represented by the following formula (I):wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.

The present invention provides a method for treating a corneal disease by administering to a patient in need of such treatment an effective amount of ozagrel or a salt thereof.

The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.

The invention discloses a working distance measuring device and measuring method of a corneal topography instrument, which is characterized in that it includes a corneal photographing component and a distance measuring optical path component. Two lenses and the first photodetector, the distance measuring optical path assembly includes a beam splitting unit, a transmitting and receiving unit and a drive motor, the beam splitting unit is arranged on the optical axis of the cornea photographing assembly, and the beam splitting unit is located between the first lens and the second lens Between, for the light transmitted into the cornea photographing assembly and the light reflected into the transmitting and receiving unit, the driving motor is used to drive the transmitting and receiving unit to move back and forth along the direction perpendicular to the optical axis of the corneal photographing assembly; the advantage is that through this The measuring device and method can accurately measure the working distance of the corneal topographer when photographing the cornea, so that the restoration accuracy of the corneal curvature is higher, thereby making the diagnosis of corneal diseases more accurate by the corneal topographer.